ETON - Eton Pharmaceuticals Inc
IEX Last Trade
4.585
-0.015 -0.327%
Share volume: 35,284
Last Updated: Fri 30 Aug 2024 09:59:50 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$4.60
-0.02
-0.33%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-11 | 2022-11-10 | 2023-03-16 | 2023-05-11 | 2023-08-10 | 2023-11-09 | 2024-03-14 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 23.046 M | 21.520 M | 25.030 M | 23.928 M | 30.932 M | 31.526 M | 31.740 M | 30.794 M | |
| Current Assets | 19.776 M | 16.420 M | 20.004 M | 19.118 M | 26.333 M | 27.157 M | 26.839 M | 24.263 M | |
| Inventories | 531.000 K | 481.000 K | 557.000 K | 437.000 K | 816.000 K | 1.051 M | 911.000 K | 2.318 M | |
| Other Current Assets | 1.365 M | 1.063 M | 1.290 M | 1.099 M | 867.000 K | 541.000 K | 1.129 M | 1.050 M | |
| Short Term Investments | 1.365 M | 1.063 M | 1.290 M | 1.099 M | 867.000 K | 541.000 K | 1.129 M | 1.050 M | |
| Total Receivables | 834.000 K | 1.498 M | 1.852 M | 2.874 M | 3.084 M | 3.495 M | 3.411 M | 4.240 M | |
| Current Cash | 17.046 M | 13.378 M | 16.305 M | 14.708 M | 21.566 M | 22.070 M | 21.388 M | 16.655 M | |
| Total Non-current Assets | 3.270 M | 5.100 M | 5.026 M | 4.810 M | 4.599 M | 4.369 M | 4.901 M | 6.531 M | |
| Property Plant Equipment | 87.000 K | 73.000 K | 72.000 K | 56.000 K | 46.000 K | 38.000 K | 58.000 K | 57.000 K | |
| Other Assets | 75.000 K | 54.000 K | 200.000 K | 181.000 K | 161.000 K | 121.000 K | 104.000 K | 86.000 K | |
| Intangible Assets | 3.108 M | 4.973 M | 4.754 M | 4.573 M | 4.392 M | 4.210 M | 4.739 M | 6.388 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 23.046 M | 21.520 M | 25.030 M | 23.928 M | 30.932 M | 31.526 M | 31.740 M | 30.794 M | |
| Total liabilities | 9.804 M | 10.339 M | 11.952 M | 12.687 M | 14.207 M | 14.634 M | 16.263 M | 15.300 M | |
| Total current liabilities | 3.812 M | 4.661 M | 6.461 M | 7.494 M | 9.588 M | 10.393 M | 16.241 M | 15.300 M | |
| Accounts Payable | 1.299 M | 1.054 M | 1.766 M | 1.233 M | 2.300 M | 1.712 M | 1.848 M | 2.263 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 364.000 K | 708.000 K | 1.033 M | 1.339 M | 1.540 M | 1.540 M | 5.380 M | 5.020 M | |
| Long term debt | 5.992 M | 5.678 M | 5.491 M | 5.193 M | 4.619 M | 4.241 M | 22.000 K | 0.000 | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 13.242 M | 11.181 M | 13.078 M | 11.241 M | 16.725 M | 16.892 M | 15.477 M | 15.494 M | |
| Common stock | 25.126 M | 25.365 M | 24.792 M | 25.525 M | 25.593 M | 25.719 M | 25.743 M | 25.763 M | |
| Retained earnings | -101.001 M | -104.046 M | -103.134 M | -105.794 M | -101.235 M | -101.814 M | -104.070 M | -104.881 M |